ライフサイエンスコーパス: 2-deoxy-D-glucose

1 ecific substrates (L-glucose, D-mannose, and 2-deoxy-D-glucose).

2 positron emission tomography using 18-fluoro-2-deoxy-d-glucose.

3 only 28% of saline controls' after systemic 2-deoxy-D-glucose.

4 ular ATP by the addition of sodium azide and 2-deoxy-D-glucose.

5 food, or glucoprivation induced by systemic 2-deoxy-D-glucose.

6 the abundance of glucose and the removal of 2-deoxy-D-glucose.

7 ed with dynamic PET imaging of [(18)F]fluoro-2-deoxy-D-glucose.

8 eripheral tissues were measured using [(3)H]-2-deoxy-D-glucose.

9 the presence of the glycosylation inhibitor 2-deoxy-d-glucose.

10 he glycolytic inhibitor WP1122, a prodrug of 2-deoxy-d-glucose.

11 Myotube 2-deoxy-D-glucose (0.05 mM) uptake was unaffected by cha

12 posure to 2, 4-dinitrophenol (50 microM) and 2-deoxy-D-glucose (10 mM) stimulated outward currents ca

13 ed by labelling cells with 2'-[(18)F]-fluoro-2'-deoxy-D-glucose ((18)F-FDG).

14 ted to lactate production and (18)F-2-fluoro-2-deoxy-D-glucose ((18)F-FDG) uptake.

15 ulticenter clinical trial using (18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole

16 The PET tracers 2-(18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), 3'-deoxy-3'-(18)F-fluorot

17 erformed with PET using 2-fluorine 18-fluoro-2-deoxy-d-glucose ((18)F-FDG).

18 ectroscopic imaging (MRSI) and [(18)F]fluoro-2-deoxy-D-glucose ((18)FDG) positron emission tomography

19 28)-A20FMDV2 was superior to 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) in imaging the BxPC-3 tum

20 2-[(18)F]fluoro-2-deoxy-D-glucose ([(18)F]FDG), which is sequestered in

21 lic activity as measured by [18F]-2-fluoro-d-2-deoxy-d-glucose (18F-FDG) PET/CT.

22 to measure regional uptake of (18F)-2-fluoro-2-deoxy-D-glucose (18FDG) following its intravenous inje

23 ience, however, with PET using 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) in carcinoid is very limited.

24 tio (DUR), a widely used index of 18F-fluoro-2-deoxy-D-glucose (18FDG) metabolism in a variety of tum

25 Inhibition of glycolysis via 2-Deoxy-D-glucose (2-DG) administration during CDI decre

26 The energy antimetabolites 2-deoxy-D-glucose (2-DG) and Na-2-mercaptoacetate (MA) b

27 The combination of 2-deoxy-D-glucose (2-DG) and UA-4 induced cell cycle arr

28 tment of macrophages with the glucose analog 2-deoxy-D-glucose (2-DG) armed phagocytes to eliminate t

29 It is well known that 2-Deoxy-d-glucose (2-DG) blocks intracellular utilizatio

30 2-deoxy-D-glucose (2-DG) has been shown to induce increa

31 ategy in vivo using the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) in combination with Adriamycin

32 2-Deoxy-d-glucose (2-DG) is a synthetic glucose analogue

33 The glucose analog 2-deoxy-D-glucose (2-DG) mimics CR effects in several an

34 effects of acute metabolic stress induced by 2-deoxy-D-glucose (2-DG) on pituitary-adrenal axis activ

35 OR complex 1 and is efficiently inhibited by 2-deoxy-d-glucose (2-DG) or by glucose starvation.

36 Inhibition of glycolysis with 2-deoxy-D-glucose (2-DG) reduced osteoclast formation an

37 Insulin-stimulated (17 nmol/l) 2-deoxy-D-glucose (2-DG) uptake was inhibited 31% in adi

38 The glycolytic inhibitor 2-deoxy-d-glucose (2-DG) was used to test the efficacy o

39 ria-targeted drugs (MTD) in combination with 2-deoxy-d-glucose (2-DG), a compound that inhibits glyco

40 2-Deoxy-d-glucose (2-DG), a synthetic glucose analogue t

41 We found that the glucose mimic, 2-deoxy-D-glucose (2-DG), blocked T/Bra expression and a

42 We studied the effects of inhibitors (2-deoxy-D-glucose (2-DG), iodoacetate (IAA)), intermedia

43 enge, intraperitoneal-administered 350 mg/kg 2-deoxy-D-glucose (2-DG), on food intake were measured i

44 atory blood glucose responses to insulin and 2-deoxy-d-glucose (2-DG).

45 ion therapy using periocular carboplatin and 2-deoxy-d-glucose (2-DG).

46 the planarians to D-glucose (1 microM) or to 2-deoxy-D-glucose (2-DG, 1 microM), but not to L-glucose

47 riment 2 tested the effects of the compound, 2-deoxy-D-glucose (2-DG, 200 and 400 mg/kg), which block

48 -(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) reports on glucose uptake and

49 2-Deoxy-D-glucose (200 and 400 mg/kg) produced selective

50 be mimicked by dietary supplementation with 2-deoxy-D-glucose (2DG) a non-metabolizable glucose anal

51 uced by the anti-metabolic glucose analogue, 2-deoxy-d-glucose (2DG) across a 4 h time course.

52 hypoglycemia and to a blunted CRR caused by 2-deoxy-d-glucose (2DG) administration.

53 It showed that two drugs, 2-deoxy-d-glucose (2DG) and metformin, effectively dimin

54 ng two drugs that affect glucose metabolism: 2-deoxy-d-glucose (2DG) and metformin.

55 The current work tests the hypothesis that 2-deoxy-d-glucose (2DG) combined with cisplatin [cis-dia

56 bition of glycolysis with the glucose analog 2-deoxy-D-glucose (2DG) during the period of exposure to

57 2-Deoxy-D-glucose (2DG) has recently received emergency

58 ng glycolysis using the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in experimental models of seizur

59 ated the effects of the glycolytic inhibitor 2-deoxy-D-glucose (2DG) in the rat kindling model of tem

60 2-Deoxy-d-glucose (2DG) is a glucose analogue that inhib

61 Because 2-deoxy-D-glucose (2DG) is a potent inhibitor of glucose

62 eatment with low doses of the glucose analog 2-deoxy-d-glucose (2DG) on ADPKD progression in ortholog

63 tory challenges as glucoprivation induced by 2-deoxy-D-glucose (2DG) or food deprivation in rodents.

64 Systemic 2-deoxy-d-glucose (2DG) produces pronounced torpor-like

65 harmacological inhibition of glycolysis with 2-deoxy-d-glucose (2DG) reversed the expansion of follic

66 ATC) with an effective glycolysis inhibitor, 2-deoxy-d-glucose (2DG) to target TIS.

67 ized in vivo by inhibiting glycolysis with a 2-deoxy-d-glucose (2DG) treatment.

68 Here, we examined the potential of 2-Deoxy-D-Glucose (2DG), a glycolysis inhibitor, to atte

69 t have either been treated or untreated with 2-deoxy-d-glucose (2DG), a pharmaceutical that targets c

70 enuated stimulation of AgRP mRNA and AMPK by 2-deoxy-d-glucose (2DG), implicating that brain GLUT2 ma

71 p.) injection of the glucose antimetabolite, 2-deoxy-D-glucose (2DG), or saline.

72 rrying the pathogenic m.3243A>G variant with 2-Deoxy-D-glucose (2DG), or the related 5-thioglucose.

73 or of glycolysis and N-linked glycosylation, 2-deoxy-D-glucose (2DG), potently inhibited surface expr

74 ere infected with HSV and treated daily with 2-deoxy-d-glucose (2DG), which inhibits glucose use via

75 ord (T2-T4) and subsequently tested rats for 2-deoxy-D-glucose (2DG)-induced feeding and blood glucos

76 experiment examined the effects of repeated 2-deoxy-D-glucose (2DG)-induced glucoprivation on subseq

77 In addition, 2-deoxy-D-glucose (2DG)-induced hyperphagia, central Ang

78 rain samples were collected from control and 2-deoxy-d-glucose (2DG)-injected rats for Western blot a

79 cylimidazole (NDI) with glycolytic inhibitor 2-deoxy-d-glucose (2DG).

80 glucose deprivation or the glucose analogue 2-deoxy-d-glucose (2DG).

81 SPN) activated by glucoprivation, induced by 2-deoxy-D-glucose (2DG).

82 2-deoxy-D-glucose (2DG; 200 mg/kg) was used to induce gl

83 cted bilaterally into A1/C1 and responses to 2-deoxy-D-glucose (2DG; 200 mg/kg)-induced glucoprivatio

84 urons by the antimetabolic glucose analogue, 2-deoxy-D-glucose (2DG; 50, 100, 200 or 400 mg/kg, s.c.)

85 Concurrent inhibition of glycolysis (2-deoxy-D-glucose, 2DG) and mitochondrial respiration (r

86 hway is also inhibited by treatments such as 2-deoxy-D-glucose (2dGlc) or glucose deprivation that in

87 essed at the yeast cell membrane and restore 2-deoxy-d-glucose, 3-O-methylglucose, and d-glucose tran

88 values for [3H]cytochalasin B binding were: 2-deoxy-D-glucose (4.5 mM) > or = D-glucose (7 mM) > man

89 2-Deoxy-D-glucose (500 mg/kg, i.p.)-induced hyperphagia

90 ntake under deprivation (24 h), glucoprivic (2-deoxy-D-glucose, 500 mg/kg, i.p.) or palatable (10% su

91 , Pi, and PPi and only modestly depressed by 2-deoxy-D-glucose 6-phosphate, a poor substrate for Glc-

92 retion caused by the central vagal stimulant 2-deoxy-D-glucose (75 mg kg(-1)), whereas bethanechol-st

93 e wall (electron component) for 2-18F-fluoro-2-deoxy-D-glucose, 99mTc-diethylenetriaminepentaacetic a

94 ts that received isotonic saline or systemic 2-deoxy-d-glucose (a glucose antimetabolite).

95 ceptor differentiation, achieved either with 2-deoxy-D-glucose, a competitive inhibitor of glucose me

96 r NSC185058, as well as glycolysis inhibitor 2-deoxy-d-glucose, abrogated beta-GlcCer-induced NETs.

97 imal semiquantitative measure of [18F]fluoro-2-deoxy-D-glucose accumulation in sarcoma and standardiz

98 s mice treated with the glycolytic inhibitor 2-deoxy-D-glucose ameliorated the disease progression an

99 Using 2-deoxy-d-glucose, an inhibitor of glucose uptake, and c

100 ns but did not alter the uptake rate of this 2-deoxy-D-glucose analog in astrocytes.

101 atment increased the uptake of a fluorescent 2-deoxy-D-glucose analog in neurons but did not alter th

102 etformin unexpectedly decreased transport of 2-deoxy-d-glucose and 3-O-methyl-d-glucose by fibroblast

103 nificantly enhanced the cytotoxic effects of 2-deoxy-D-glucose and caused increases in endpoints indi

104 in fed mice pre-treated with 500 mg/kg i.p. 2-deoxy-D-glucose and in hypoglycemic mice fasted for 30

105 In contrast, GH decreased uptake of 2-deoxy-d-glucose and levels of Glut1 protein.

106 We monitor environmentally (2-deoxy-D-glucose) and genetically (DeltaPFK2) perturbed

107 jury which employs inhibitors of glycolysis (2-deoxy-D-glucose) and oxidative phosphorylation (antimy

108 Analysis of 3-O-methylglucose, 2-deoxy-D-glucose, and D-glucose uptake in the presence

109 functionality by inducing energy stress with 2-deoxy-D-glucose, and demonstrated that Q10, together w

110 sitron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose, and general intellectual functions, m

111 ls were continuously treated (24 hours) with 2-deoxy-D-glucose, and total glutathione content as well

112 mission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose as a radiotracer.

113 increased bone marrow (BM) 2-((18)F) fluoro-2-deoxy-D-glucose as a tracer (FDG)-uptake in patients w

114 died with dynamic PET imaging of [18F]fluoro-2-deoxy-D-glucose at two occasions with 24-hour interval

115 graphy after an injection of [(18)F]2-fluoro-2-deoxy-d-glucose before the OGTT, and the rate of gluco

116 formed dynamic [(15)O]H2O and [(18)F]-fluoro-2-deoxy-d-glucose brain positron emission tomography sca

117 PET with [18F]fluoro-2-deoxy-D-glucose can be used to image cellular metaboli

118 PET with [(18)F]fluoro-2-deoxy-D-glucose can be used to image cellular metaboli

119 treatment of human breast cancer cells with 2-deoxy-d-glucose causes metabolic oxidative stress that

120 se results suggest that either D-glucose and 2-deoxy-D-glucose compete with a common cocaine and kapp

121 of the purified protein showed quenching by 2-deoxy-D-glucose, D-mannose, D-glucose or D-galactose i

122 On the other hand, 2-deoxy-d-glucose decreased the LPS-induced iNOS gene ex

123 urthermore, administering the glucose analog 2-deoxy-D-glucose delayed AMKL progression and promoted

124 (ATP), and an inhibitor of energy metabolism 2-deoxy-D-glucose (DeOGlc) + sodium iodoacetate (IAc), o

125 e a comparable reduction of ATP levels (with 2-deoxy-D-glucose) did not induce these changes.

126 en when glucose utilization was blocked with 2-deoxy-D-glucose during the later part of the hypoxic p

127 T could be strongly inhibited by glucose and 2-deoxy-d-glucose even though the latter was not a good

128 Inhibiting GCL activity during 2-deoxy-D-glucose exposure using l-buthionine-[S,R]-sulf

129 uman cancers can be imaged by 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) and PET, there is little clinica

130 malignant tumors with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) as a tracer is a noninvasive dia

131 2-[18F]-Fluoro-2-deoxy-d-glucose (FDG) cell labeling also was evaluated

132 emission tomography (PET) with [18F]-fluoro-2-deoxy-D-glucose (FDG) for lymph node staging in patien

133 Uptake of 2-[18F]-2-deoxy-D-glucose (FDG) has been used as a marker of inc

134 and cerebral metabolism using [(18)F]fluoro-2-deoxy-d-glucose (FDG) in Alzheimer's disease (AD) pati

135 ts infused with the glucose analog, 2-fluoro-2-deoxy-D-glucose (FDG) in vivo.

136 [18F]fluoro-2-deoxy-D-glucose (FDG) is a glucose analogue radiopharm

137 PET with 18F-fluoro-2-deoxy-D-glucose (FDG) is currently the noninvasive gol

138 by which tumor cells take up 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG) is heterogeneous and influenced

139 Modern techniques, such as [(18)F]2-fluoro-2-deoxy-D-glucose (FDG) PET-CT scans, might provide furt

140 Ga]Ga-PSMA-11 and 2-flourine-18[(18)F]fluoro-2-deoxy-D-glucose (FDG) PET-CT scans.

141 was applied to dynamic 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomographic (P

142 -attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

143 Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

144 8F]fluorodopamine ([18F]FDA) and [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PE

145 (MRGlc) in brain with PET and 2-[18F]fluoro-2-deoxy-D-glucose (FDG) requires knowing the rate of upt

146 ficity, and clinical utility of 18F 2-fluoro-2-deoxy-D-glucose (FDG) total-body positron emission tom

147 Although 2[18F]fluoro-2-deoxy-d-glucose (FDG) uptake during positron emission

148 into the origin of the (18)fluorine-labeled 2-deoxy-D-glucose (FdG) uptake signals observed clinical

149 mography (PET/CT) scanner with [F-18]-fluoro-2-deoxy-D-glucose (FDG) was evaluated.

150 After 20 mCi of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) were administered intravenously,

151 In this study, the utility of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) whole-body PET was evaluated as

152 er glucose metabolic changes in (18)F-fluoro-2-deoxy-D-glucose (FDG)-PET images are associated with e

153 otential cost-effectiveness of [18F]2-fluoro-2-deoxy-D-glucose (FDG)-PET in the management of SPN.

154 dy, we assessed the utility of [18F]2-fluoro-2-deoxy-D-glucose (FDG)-PET in understanding dystonia pa

155 the labeled glucose analogue 2[(18)F]fluoro-2-deoxy-D-glucose (FDG).

156 olysis by replacing glucose in the bath with 2-deoxy-D-glucose had no effect.

157 sitron emission tomography using [18F]fluoro-2-deoxy-D-glucose has been studied as a tool to help pre

158 lammation using PET imaging of [(18)F]fluoro-2-deoxy-D-glucose in a porcine experimental model of ear

159 nstrate promise for the use of topotecan and 2-deoxy-D-glucose in children.

160 ATP depletion (5 mm NaCN and 5 mm 2-deoxy-d-glucose in the absence of medium glucose) caus

161 For example, in our system, sodium azide and 2-deoxy-D-glucose increased the ratio of cellular AMP to

162 s are treated with the hexokinase inhibitor, 2-deoxy-d-glucose, indicating that a functional glycolyt

163 dative stress and sensitizes cancer cells to 2-deoxy-D-glucose-induced cytotoxicity.

164 sponses elicited by food deprivation (24 h), 2-deoxy-D-glucose-induced glucoprivation (500 mg/kg) or

165 A receptor antagonism in both sites to alter 2-deoxy-D-glucose-induced intake, mercaptoacetate-induce

166 ivity was enhanced by glucose and reduced by 2-deoxy-D-glucose-induced starvation.

167 -deoxy-d-glucose uptake equals K(i(app)) for 2-deoxy-d-glucose inhibition of 3-O-methylglucose uptake

168 2-Deoxy-D-glucose, inhibits glucose metabolism and has b

169 aphy (PET) with FDG-glucose (2-[(18)F]fluoro-2-deoxy-d-glucose) is already being used as a metabolic

170 A combination of 2-deoxy-D-glucose, mannoheptulose and 3-0-methyl-glucose

171 Furthermore, inhibition of 2-deoxy-D-glucose-mediated induction of GCL activity wit

172 3 receptor (D3R) in the feeding responses to 2-deoxy-D-glucose, mercaptoacetate, and peripheral insul

173 strain had a significant effect on [F]fluoro-2-deoxy-D-glucose net uptake rate Ki in high-strain lipo

174 poglycemia produced by exogenous insulin and 2-deoxy-D-glucose on glucagon secretion.

175 H or RVLM was elicited by microinjections of 2-deoxy-D-glucose or 5-thio-D-glucose in anesthetized, e

176 atments of B6.Sle1Sle2.Sle3 mice with either 2-deoxy-D-glucose or metformin were sufficient to preven

177 isease patients had cerebral 2-[(18)F]fluoro-2-deoxy-D-glucose PET ((18)FDG-PET), the results of whic

178 and sex-matched controls using 18F-2-fluoro-2-deoxy-d-glucose PET (n = 20 per group) and voxel-based

179 ncurrent EEG sleep studies and [(18)F]fluoro-2-deoxy-D-glucose PET scans during waking and NREM sleep

180 2-Fluoro-2-deoxy-D-glucose/PET studies in which glioma glucose me

181 creasing the rate of intracellular [F]fluoro-2-deoxy-D-glucose phosphorylation.

182 Using 2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography ((18)F-FD

183 ognized and is exploited with (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FD

184 2-[(18)F]Fluoro-2-deoxy-d-glucose positron emission tomography ([(18)F]F

185 Imaging with 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET)

186 e of this study was to compare 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)

187 the prognostic role of interim [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)

188 bolism, a phenomenon used in 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography imaging o

189 obese normal subjects with [(18)F]-2-fluoro-2-deoxy-D-glucose positron emission tomography imaging.

190 ecent developments in the use of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the cl

191 The utility of 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography integrate

192 of autoimmune pancreatitis (6) 2-(18F)-Fluro-2-deoxy-D-glucose positron emission tomography might be

193 [18F]fluoro-2-deoxy-D-glucose positron emission tomography should no

194 [18F]fluoro-2-deoxy-D-glucose positron emission tomography should no

195 We used 2-[18F]-2-deoxy-D-glucose positron emission tomography to examin

196 [18F]fluoro-2-deoxy-D-glucose positron emission tomography will like

197 in these subjects by means of [(18)F]fluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed

198 ithout active cancer underwent 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed

199 cardiography in SAB, including 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed

200 The 2-[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)

201 identified by FDG-PET-CT (2-[(1)(8)F]fluoro-2-deoxy-D-glucose-positron emission tomography combined

202 cal, neuropsychological, and 2-[(18)F]fluoro-2-deoxy-d-glucose-positron emission tomography examinati

203 ars ago and currently exploited for 2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging i

204 Early restaging fluoro-2-deoxy-D-glucose-positron emission tomography scans app

205 apted therapy on the basis of interim fluoro-2-deoxy-D-glucose-positron emission tomography scans hav

206 (ATGU) glucose uptake with [(18) F]2-fluoro-2-deoxy-D-glucose/positron emission tomography, lipolysi

207 objective of this MRI-guided 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)

208 furan product was formed, whereas the use of 2-deoxy-d-glucose resulted in reduced chemo- and stereos

209 of the response of yeast relative fitness to 2-deoxy-D-glucose reveals that control is distributed be

210 on emission tomography with [(18)F]-2-fluoro-2-deoxy-D-glucose scan in addition to noncontrast comput

211 of mechanical ventilation, dynamic [F]fluoro-2-deoxy-D-glucose scans were acquired to quantify metabo

212 le mice, inhibiting branched N-glycans using 2-Deoxy-D-glucose sensitizes HR-proficient, but not HR-d

213 ionine sulfoximine or energy depletion using 2-deoxy-D-glucose/sodium azide restored flutamide accumu

214 Thus, our findings are in accord with 2-Deoxy-D-glucose studies performed in V1 of macaques an

215 itron emission tomography and [18F]-2-fluoro-2-deoxy-D-glucose to determine cerebral metabolism.

216 We demonstrate defects in insulin action on 2-deoxy-D-glucose transport (SHRSP 3.3 +/- 1.5 vs. 21.0

217 during both AICAR and insulin infusion; [3H]2-deoxy-D-glucose transport activity increased to a simi

218 AICAR stimulated 2-deoxy-D-glucose transport twofold and reduced insulin-

219 hotoirradiated cells even in glucose-free or 2-deoxy-D-glucose-treated conditions.

220 in glucose-free medium or in the presence of 2-deoxy-D-glucose upon CCCP treatment.

221 2 to alanine (Q282A) doubled the Km(app) for 2-deoxy-d-glucose uptake and eliminated cis-allostery (s

222 l state, Q209L-Galphaq expression stimulated 2-deoxy-D-glucose uptake and GLUT4 translocation to 70%

223 A 2-deoxy-d-glucose uptake assay indicates that depletion

224 Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated with noncalcified (B

225 Hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake associated with noncalcified (b

226 In soft tissue sarcomas, [18F]fluoro-2-deoxy-D-glucose uptake correlates with histologic grad

227 transport in human red cells, K(m(app)) for 2-deoxy-d-glucose uptake equals K(i(app)) for 2-deoxy-d-

228 hose with high hepatic 2-[fluorine-18]fluoro-2-deoxy-D-glucose uptake had higher noncalcified (1.3 [0

229 reased the potency of insulin in stimulating 2-deoxy-D-glucose uptake in 3T3-L1 adipocytes, with a de

230 , we demonstrate that increased [18F]-fluoro-2-deoxy-D-glucose uptake in the right dorsolateral prefr

231 Reduction in [18F]fluoro-2-deoxy-D-glucose uptake is an early predictor of histol

232 Tidal strain enhances local [F]fluoro-2-deoxy-D-glucose uptake primarily by increasing the rat

233 [18F]fluoro-2-deoxy-D-glucose uptake rate was computed for the total

234 [(18)F]fluoro-2-deoxy-D-glucose uptake rate was computed for the whole

235 When 2-deoxy-D-glucose uptake was measured in these cells, th

236 Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose

237 er 5 days, muscle weights and ex vivo [(3)H]-2-deoxy-d-glucose uptake were assessed.

238 ll effects were observed on IGF-1-stimulated 2-deoxy-D-glucose uptake.

239 nt or tidal hyperinflation had [(18)F]fluoro-2-deoxy-D-glucose uptakes similar to controls.

240 termediate gravitational zones [(18)F]fluoro-2-deoxy-D-glucose uptakes were higher in ventilator-indu

241 in oocytes were lower than maximal rates for 2-deoxy-d-glucose (Vmax of 224 and 32 pmol/min/oocyte fo

242 Injection of 2-deoxy-D-glucose was found to increase hemolymph glucos

243 ission tomography (PET) with [(18)F]2-fluoro-2-deoxy-D-glucose was used to measure changes in regiona

244 of radiolabelled D-glucose, D-galactose and 2-deoxy-D-glucose were restored, consistent with the exp

245 llular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, an

246 reating infected cells with sodium azide and 2-deoxy-D-glucose, which we show rapidly and reversibly

247 riphosphate], is abolished by ATP depletion (2 deoxy-D-glucose with oligomycin or perfusion of apyras

248 s muscles were incubated ex vivo with [(3)H]-2-deoxy-d-glucose, with or without insulin or AICAR, bef